CU24049B1 - Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) - Google Patents

Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)

Info

Publication number
CU24049B1
CU24049B1 CU2011000044A CU20110044A CU24049B1 CU 24049 B1 CU24049 B1 CU 24049B1 CU 2011000044 A CU2011000044 A CU 2011000044A CU 20110044 A CU20110044 A CU 20110044A CU 24049 B1 CU24049 B1 CU 24049B1
Authority
CU
Cuba
Prior art keywords
aminophenyl
benzamide
methyl
polymorph
metoxicarbonylamine
Prior art date
Application number
CU2011000044A
Other languages
English (en)
Other versions
CU20110044A7 (es
Inventor
Matthias Schneider
Michael Gottfried
Jens Geisler
Gabriele Winter
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/006381 external-priority patent/WO2010022988A1/en
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20110044A7 publication Critical patent/CU20110044A7/es
Publication of CU24049B1 publication Critical patent/CU24049B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El polimorfo B cristalino de N-(2-aminofenil)-4-[N-(piridin-3-il)metoxicarbonilamino-metil]benzamida (MS-275) de fórmula I ESPACIO PARA LA FÓRMULA el cual es útil para tratar tumores malignos, enfermedades autoinmunes, enfermedades dermatológicas y parasitismo. También se describe el proceso para producir dicho compuesto.
CU2011000044A 2008-08-29 2011-02-28 Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) CU24049B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (2)

Publication Number Publication Date
CU20110044A7 CU20110044A7 (es) 2011-12-28
CU24049B1 true CU24049B1 (es) 2014-12-26

Family

ID=40791975

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000044A CU24049B1 (es) 2008-08-29 2011-02-28 Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)

Country Status (2)

Country Link
CU (1) CU24049B1 (es)
GB (1) GB2462893B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa

Also Published As

Publication number Publication date
GB2462893B (en) 2010-10-13
GB0907347D0 (en) 2009-06-10
CU20110044A7 (es) 2011-12-28
GB2462893A (en) 2010-03-03

Similar Documents

Publication Publication Date Title
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
EA201000113A1 (ru) Пиразольные соединения
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
EA201400245A1 (ru) Ингибиторы dyrk1 и их применение
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
EA201100299A1 (ru) Органические соединения
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
EA201291246A1 (ru) Конденсированные бициклические ингибиторы киназы
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
GB201114389D0 (en) Novel compounds
CU24049B1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
TW200635905A (en) Processes for producing 4-aminoquinazolines
UA85701C2 (ru) Способ получения ингибиторов триптазы
GT200600207A (es) Proceso para la síntesis de compuestos orgánicos

Legal Events

Date Code Title Description
FG Grant of patent